AnaptysBio, Inc. (ANAB)

NMS – Real vaqt narxi. Valyuta: USD

65.58

-2.34 (-3.45%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

11.05.2026

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.

06.05.2026

AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?

Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's find out.

05.05.2026

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.

04.05.2026

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET.

28.04.2026

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New England Journal of Medicine (NEJM) Evidence1. The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration (FDA) with a target action date of December 12, 2026.

28.04.2026

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

11.05.2026

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

28.04.2026

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

24.04.2026

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro's anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys' position that it has never repudiated the Collaboration and Exclusive License Agreement (“Collaboration Agreement”) with Tesaro, a subsidiary of GSK, governing the development and commercialization of Jemperli.

AnaptysBio, Inc. (ANAB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AnaptysBio, Inc. (ANAB)

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Videolar

No Data

Press-relizlar

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Videolar

No Data

Press-relizlar

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

Search stocks

AnaptysBio, Inc. (ANAB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AnaptysBio, Inc. (ANAB)

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Videolar

No Data

Press-relizlar

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Videolar

No Data

Press-relizlar

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim